Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma

Ting Yan(Shanxi Medical University), Heyang Cui(Shanxi Medical University), Yong Zhou(Shanxi Medical University), Bin Yang(Shanxi Medical University), Pengzhou Kong(Shanxi Medical University), Yingchun Zhang(Shanxi Medical University), Yiqian Liu(Shanxi Medical University), Bin Wang(Hong Kong University of Science and Technology), Yikun Cheng(Berkeley College), Jiayi Li(Singapore College of Traditional Chinese Medicine), Shixing Guo(Shanxi Medical University), Enwei Xu(Shanxi Medical University), Huijuan Liu(Shanxi Medical University), Caixia Cheng(Shanxi Medical University), Ling Zhang(Shanxi Medical University), Ling Chen(Nankai University), Xiaofei Zhuang(Shanxi Provincial Cancer Hospital), Yu Qian(Shanxi Medical University), Jian Yang(Shanxi Medical University), Yanchun Ma(Shanxi Medical University), Hongyi Li(Shanxi Medical University), Fang Wang(Shanxi Medical University), Jing Liu(Shanxi Medical University), Xuefeng Liu(Hong Kong University of Science and Technology), Dan Su(Zhejiang Cancer Hospital), Yan Wang(Hong Kong University of Science and Technology), Ruifang Sun(Shanxi Provincial Cancer Hospital), Shiping Guo(Shanxi Medical University), Yaoping Li(Shanxi Medical University), Xiaolong Cheng(Shanxi Medical University), Zhihua Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Qimin Zhan(Peking University), Yongping Cui(Shanxi Medical University)
Nature Communications
April 11, 2019
Cited by 149Open Access
Full Text

Abstract

Esophageal squamous cell carcinoma (ESCC) ranks fourth among cancer-related deaths in China due to the lack of actionable molecules. We performed whole-exome and T-cell receptor (TCR) repertoire sequencing on multi-regional tumors, normal tissues and blood samples from 39 ESCC patients. The data revealed 12.8% of ERBB4 mutations at patient level and functional study supported its oncogenic role. 18% of patients with early BRCA1/2 variants were associated with high-level contribution of signature 3, which was validated in an independent large cohort (n = 508). Furthermore, knockdown of BRCA1/2 dramatically increased sensitivity to cisplatin in ESCC cells. 5% of patients harbored focal high-level amplification of CD274 that led to massive expression of PD-L1, and might be more sensitive to immune checkpoint blockade. Finally, we found a tight correlation between genomic and TCR repertoire intra-tumor heterogeneity (ITH). Collectively, we reveal high-level ITH in ESCC, identify several potential actionable targets and may provide novel insight into ESCC treatment.


Related Papers

No related papers found

Powered by citation graph analysis